BIIB - Biogen Inc

NASDAQ · Healthcare · Drug Manufacturers—General

$177.35

Market Closed

End of day · Apr 17, 2026, 12:00 AM

Active

Resolved

Bull

Bear

About

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It also provides RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, immunology related diseases, neurovascular disorders, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. Biogen Inc. has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

https://www.biogen.com

BIIB - Biogen Inc

Healthcare

BIIB's had a pretty strong run over the last year. If you look at where it was last April (flirting with 115), it's been through some healthy swings but mostly up and to the right. The climb from Q2 last year really picked up steam in November, and it's held on to a lot of those gains even with a few dips and some obvious volatility. Now it's at 172.97 and I don't see the same room for easy upside as before. I'm leaning bearish here with a target price of 155.00. A couple reasons: first, a lot of the recent excitement was around pipeline readouts and one off headlines, but the fundamentals haven't shifted as much as the chart makes it look. Revenue growth is still sluggish and while their Alzheimer's portfolio keeps getting attention, it's not clear to me there's a strong ramp coming this year. Plus, competition in neuro goes up every year and payor skepticism isn't going away. There's a real risk that guidance for the next quarter comes in soft and that alone could give BIIB a reality check. To be fair, if they pull off something surprising in the next set of earnings (or an unexpected positive trial update hits), this could squeeze higher and I'd look dumb. That's probably the main catalyst to keep an eye on whatever gets said in their next call could move the needle quickly, especially with sentiment still hot after the recent run up. But at this price, I think the easy money's been made unless you have high conviction on a near term positive surprise. For me, it's time to get cautious.

Entry

$172.97

Below

$155.00

Jun 6, 2026

Karma

125 to 17562

Bearish

Open

Vote